Lakewood-Amedex (LABT) Stock Price, News & Analysis
Company Description
Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biotechnology company developing antimicrobial drug candidates for infectious diseases. The company’s research is centered on the Bisphosphocin® class, a novel class of fast-acting, broad-spectrum antimicrobials discovered by Lakewood-Amedex and intended to address bacterial infections, including strains associated with antimicrobial resistance such as MRSA and VRE. Its common stock trades on the Nasdaq Capital Market under the symbol LABT following an April 2026 direct listing.
Antimicrobial platform and lead compound
The company’s lead compound, Nu-3, is being developed as a topically delivered antimicrobial treatment for infected diabetic foot ulcers. Lakewood-Amedex describes Nu-3 as part of its Bisphosphocin platform. Reported in vitro data for the class indicate rapid bacterial killing through pH- and concentration-dependent destabilization of bacterial cell membranes. The platform is also being explored in preclinical studies for potential use in complicated urinary tract infection and pulmonary infections.
Lakewood-Amedex’s operating model is based on advancing proprietary antimicrobial compounds through research, preclinical work, clinical development, and regulatory preparation. As a clinical-stage biotechnology issuer, the company’s durable business profile is defined by its drug-development pipeline rather than commercial product sales.
Public company status
Lakewood-Amedex Biotherapeutics is incorporated in Nevada and maintains principal executive offices in University Park, Florida. Its SEC registration materials identify the company within pharmaceutical preparations. Public-company disclosures for LABT cover securities registration, corporate governance, board composition, capital structure, business risks, and updates related to its antimicrobial development programs.
Stock Performance
Lakewood-Amedex (LABT) stock last closed at $2.02. At a market capitalization of $3.4M, LABT is classified as a micro-cap stock with approximately 1.8M shares outstanding.
LABT Rankings
Latest News
Lakewood-Amedex has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 6 with negative movement. Key topics include clinical trial. View all LABT news →
SEC Filings
Lakewood-Amedex has filed 5 recent SEC filings, including 2 Form 424B3, 1 Form PRE 14A, 1 Form 8-K, 1 Form SCHEDULE 13G. The most recent filing was submitted on July 30, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all LABT SEC filings →
Financial Highlights
Upcoming Events
Short Interest History
Short interest in Lakewood-Amedex (LABT) currently stands at 24.0 thousand shares, down 36.4% from the previous reporting period, representing 4.1% of the float. Since April 2026, short interest has decreased by 68.3%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Lakewood-Amedex (LABT) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed.
LABT Company Profile & Sector Positioning
Lakewood-Amedex (LABT) operates in the Biotechnology industry within the broader Pharmaceutical Preparations sector and is listed on the NASDAQ.